Carlo Gambacorti-Passerini - PDFSEARCH.IO - Document Search Engine

Carlo Gambacorti-Passerini
Results: 15

#	Item
1	th 6 Meeting of the European Research Initiative on ALK-related Malignancies Add to Reading List Source URL: erialcl.net Language: English - Date: 2015-09-30 10:24:57 Lymphoma Anaplastic large-cell lymphoma Piperidines Medicine Anaplastic lymphoma kinase Nomenclature of Territorial Units for Statistics Chemistry Crizotinib Carlo Gambacorti-Passerini ALK Whring Vienna
2	PDF Document Add to Reading List Source URL: erialcl.net Language: English - Date: 2015-10-05 11:40:28 Protein kinase inhibitors Piperidines Lymphoma Carlo Gambacorti-Passerini Anaplastic large-cell lymphoma Clinical medicine Chemistry Anaplastic lymphoma kinase Cancer ALK inhibitor Passerini Brigatinib
3	Articles and Brief Reports Chronic Myeloid Leukemia Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials Add to Reading List Source URL: michorlab.dfci.harvard.edu Language: English - Date: 2012-10-16 11:38:35 Medicine Clinical medicine Pyrimidines Pyridines Cancer Stem cells Piperazines Chronic myeloid leukemia Imatinib Chronic myelogenous leukemia Carlo Gambacorti-Passerini Philadelphia chromosome
4	3rd Meeting of the European Research Initiative on ALCL Punting on the River Cam with the chapel of King’s College in the background Add to Reading List Source URL: erialcl.net Language: English - Date: 2015-09-29 07:00:59 RTT Clinical medicine Medicine Cancer Lymphoma Anaplastic large-cell lymphoma Piperidines Anaplastic lymphoma kinase Carlo Gambacorti-Passerini CD30 ALK Crizotinib
5	Early Stage researcher (ESR) PhD Projects ESR 1 Investigation of the nuclear functions of ALK Duration: 3 years Start: before August 2016 Add to Reading List Source URL: alkatras.erialcl.net Language: English - Date: 2016-04-15 08:51:39 Protein kinase inhibitors Piperidines Anaplastic lymphoma kinase Lymphoma Lung cancer ALK inhibitor Anaplastic large-cell lymphoma Crizotinib Non-small-cell lung carcinoma ALK Ceritinib Carlo Gambacorti-Passerini
6	* ---------------------------------- ILTE STUDY NEWSLETTER – February 2007 ------------------------------* Dear Investigator, We would like to provide you with some further instruction to ease the use of the ILTE_part1 Add to Reading List Source URL: www.ilte-cml.org Language: English - Date: 2010-01-04 03:58:01 Carlo Gambacorti-Passerini Oncologists Imatinib Fluorescence in situ hybridization Metaphase Biology Cytogenetics Genetics
7	* ---------------------------------- ILTE STUDY NEWSLETTER – March 2007 -------------------------* Dear Investigator, This letter contains relevant information for the centres where the ILTE_part1.mdb was not fully com Add to Reading List Source URL: www.ilte-cml.org Language: English - Date: 2010-01-04 03:58:02 Carlo Gambacorti-Passerini Oncologists Valsecchi
8	* ---------------------------------------- ILTE STUDY NEWSLETTER – December 2009 ----------------------------------* Dear ILTE investigators, the third ILTE investigators meeting took place in New Orleans on December Add to Reading List Source URL: www.ilte-cml.org Language: English - Date: 2010-01-04 03:58:00 Chemistry Laboratory techniques Biochemistry Biotechnology Carlo Gambacorti-Passerini Oncologists Reverse transcription polymerase chain reaction Biology Polymerase chain reaction Molecular biology
9	* ---------------------------------- ILTE STUDY NEWSLETTER – December 2007 ------------------------------* Add to Reading List Source URL: www.ilte-cml.org Language: English - Date: 2010-01-04 03:57:59 Imatinib Organic chemistry Carlo Gambacorti-Passerini Oncologists Valsecchi
10	Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients C. Gambacorti-Passerini1, D.W. Kim2, F.X. Mahon3, G. Saglio4, F. Pane5, F. Guilhot6, M. W.N. Deininger7, A. Nagler8, A. Rambald Add to Reading List Source URL: www.ilte-cml.org Language: English - Date: 2010-01-04 03:57:59 Imatinib Pyridines Chronic myelogenous leukemia Carlo Gambacorti-Passerini Organic chemistry Piperazines Pyrimidines Oncologists

UPDATE